The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells

Journal of Neural Transmission

Volumn 109, Issue 4, 2002, Pages 467-481

  Maruyama, W ^a   Takahashi, T ^b   Youdim, M ^c   Naoi, M ^d  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b Aichi Konan College   (Japan)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d Institute of Applied Biochemistry   (Japan)

Author keywords

Apoptosis; Dopamine neuron; Mitochondrial membrane potential; Parkinson's disease; Peroxynitrite; Rasagiline

Indexed keywords

ANTIPARKINSON AGENT; CLORGYLINE; HOE 33342; PARGYLINE; PEROXYNITRITE; RASAGILINE; SELEGILINE;

APOPTOSIS; ARTICLE; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; INCUBATION TIME; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NEUROBLASTOMA CELL; NEUROPROTECTION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANTIPARKINSON AGENTS; APOPTOSIS; DNA DAMAGE; DOPAMINE; HUMANS; INDANS; MEMBRANE POTENTIALS; MITOCHONDRIA; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; PEROXYNITROUS ACID; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0036206323     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020200038     Document Type: Article

References (53)

1. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease
2. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil
3. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study
4. Effect of ethylcholine mustard aziridinium (AF64A) and of the monoamine oxidase-B-inhibitor L-deprenyl on the morphology of the rat hippocampus
5. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat
6. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover
7. Dichlorodihydrofluorescein and dihydrorhodamine 123 are sensitive indicators of peroxynitrite in vitro: Implications for intracellular measurement of reactive nitrogen and oxygen species
8. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons
9. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B
10. Selective irreversible propargyl derivative inhibitors of monoamine oxidase (MAO) without the cheese effect
11. Pharmacology of rasagiline (N-propargyl-1R-aminoindan)
12. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors
13. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B
14. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse
15. Glyceraldehyde-3-phosphate dehydrogenase anti-sense oligodeoxynucleotides protect against cytosine arabinonucleoside-induced apoptosis in cultured cerebellar neurons
16. The role of iron in neurodegeneration: Prospects for pharmacotherapy of Parkinson's disease
17. Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B
18. Some puzzling pharmacological effects of monoamine oxidase inhibitors
19. Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium
20. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl
21. The mitochondrial death/life regulator in apoptosis and necrosis
22. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo
23. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds
24. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update
25. A neurotoxin N-methyl(R)salsolinol induces apoptotic cell death in differentiated human dopaminergic neuroblastoma SH-SY5Y cells
26. An endogenous dopaminergic neurotoxin, N-methyl-(R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells
27. Neurotoxin induced apoptosis in dopamine neurons: Protection by propargylamine derivatives, Rasagiline and TV 1022
28. Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline
29. Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: Suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine
30. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion
31. Oxidation of N-methyl(R) salsolinol: Involvement to neurotoxicity and neuroprotection by endogenous catechol isoquinolines
32. Clinical trials with rasagiline mesylate: A new drug for treatment of -induced DNA damage in individual mammalian cells
33. Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells
34. Effect of deprenyl on the progression of disability in early Parkinson's disease
35. Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
36. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl
37. Selective inhibition of monoamine oxidase type B by propargyl-containing drugs
38. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of mouse and cognition disorders
39. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat
40. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: Highly selective and potent inhibitors of monoamine oxidase B
41. Etiology of Parkinson's disease
42. Selegiline can mediate neuronal rescue rather than neuronal protection
43. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration
44. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis
45. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: Time course and modification by (-)-deprenyl
46. The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction
47. Neuroprotective properties of the antiparkinson drug rasagiline and its optical S-Isomer
48. Rasagiline [N-Propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B
49. The antiparkinson drug rasagiline and its derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo
50. Aliphatic propargylamines: Potent, selective, irreversible monoamine oxidase B inhibitors
51. Neuroprotection by R(-)-deprenyl and N-2-hexyl-N-methylpropargylamine on DSP-4, a neurotoxin, induced degeneration of noradrenergic neurons in the rat locus coeruleus